

## Documents

### About CMDh

---

❖ **CMDh Composition** (<http://www.hma.eu/260.html>)

Compiled List of CMDh Members

---

❖ **CMDh Activities** (<http://www.hma.eu/205.html>)

CMDh – Rules of Procedure

Function and tasks of CMDh

Role of the Vice Chairperson of the CMDh

Evaluation of the functioning of the CMDh

---

❖ **CMDh Work plan** (<http://www.hma.eu/206.html>)

CMDh Work plan for 2011

CMDh Work plan for 2010

CMDh Work plan for 2009

## Documents

---

CMDh Work plan for 2008

CMDh Work plan for 2007

---

### ❖ **CMDh Reports** (<http://www.hma.eu/207.html>)

Summary of CMDh Activities in 2010

Summary of CMDh Activities in 2009

Summary of CMDh Activities in 2008

Summary of CMDh Activities in 2007

Summary of CMDh Activities in 2006

Summary of MRFG/CMDh Activities in 2005

Report on the evaluation of the functioning of the CMDh

---

### ❖ **Contacts with Representative Organisations** (<http://www.hma.eu/208.html>)

Contacts with Representative Organisations

Meeting with Interested Parties – 14 November 2011

Meeting with Interested Parties – 20 June 2011

Meeting with Interested Parties on the Self-Medication Project - 20 June 2011

Meeting with Interested Parties – 15<sup>th</sup> November 2010

Meeting with Interested Parties on Paediatric Regulation – 20<sup>th</sup> September 2010

Meeting with Interested Parties – 21<sup>st</sup> June 2010

Meeting with Interested Parties – 16<sup>th</sup> November 2009

Meeting with Interested Parties on Paediatric Regulation – 21<sup>st</sup> September 2009

Meeting with Interested Parties – 16<sup>th</sup> December 2008

Meeting with Interested Parties – 12<sup>th</sup> November 2007

Meeting with EGA on Work-sharing for patient consultation – 19<sup>th</sup> June 2007

Meeting with Interested Parties-13<sup>th</sup> November 2006

Request for Marketing Authorisation Holders to assess the risk of occurrence of contamination with mesilate esters and related compounds in pharmaceuticals

Request for Marketing Authorisation Holders for medicinal products presented as pressurised metered dose inhalers (pMDI)

---

❖ **Transparency Measures** (<http://www.hma.eu/209.html>)

Position paper on transparency policy of the CMDh

---

❖ **Calendar for CMDh** (<http://www.hma.eu/115.html>)

---

❖ **MRFG(1995-2005)** (<http://www.hma.eu/89.html>)

Summary of MRFG Activities in 2005

Introduction to the Mutual Recognition Facilitation Group

---

**Statistics** (<http://www.hma.eu/87.html>)

---

## Documents

**Press Releases** (<http://www.hma.eu/249.html>)

---

## **Procedural Guidance**

---

❖ **General Information** (<http://www.hma.eu/90.html>)

Best Practice Guide for the Reference Member State in the Mutual Recognition and Decentralised Procedures

CMDh procedural advice on changing the RMS

Best Practice Guide for the exchange of regulatory and administrative information regarding orphan medicinal products between EMEA and National Competent Authorities

CMDh Agreement on sunset clause and its application to marketing authorisations granted in more than one MS

Phasing in EU procedures: MRP and referrals

Notifications to the EMEA/CHMP in the Mutual Recognition/Decentralised Procedure

CMDh Recommendation for Marketing Authorisation Holders on the Pharmacovigilance System and Risk Management Plan in the Mutual Recognition and Decentralised Procedures

CMDh Best Practice Guide for the public assessment report in the decentralised and mutual recognition procedures

---

❖ **Application for Marketing Authorisation** (<http://www.hma.eu/91.html>)

Best Practice Guide for Decentralised and Mutual Recognition Procedures

Best Practice Guide on Assessment Report in the Mutual Recognition and Decentralised Procedures

Best Practice Guide on Break-out sessions for Mutual Recognition and Decentralised Procedures

Recommendations on Informed consent applications in Mutual Recognition and Decentralised Procedures

## Documents

Recommendations on Multiple applications in Mutual Recognition Procedures

MS Recommendations on Extension applications in Mutual Recognition and Decentralised Procedures

Procedural advice on Repeat Use

Declaration form for the submission of DPPS already approved by a competent authority

CMDh guidance for Declaration form submission DDPS already approved by a competent authority

---

### ***Validation Procedure***

Member state agreement upon conditions under which the RMS can start MRP/DCP

Procedural advice - Automatic Validation of MR/Repeat-Use/DC Procedures

Introduction to published papers on validation

Additional Data requested for new applications in the MRP/DCP

Common grounds for invalidation/delaying validation

MS recommendations on the Cover Letter for new applications submitted through MRP/DCP

CMDh BPG on the Compilation of the Dossier for New Applications submitted in MRP/DCP

Templates for the cover letter for new applications in MRP/DCP

---

### o ***DCP***

Decentralised procedure - Member States' SOP

## Documents

---

Recommendations on submission dates for Applicants of the Decentralised Procedure

Flow chart of the decentralised procedure

---

### ***Requests to act as RMS in DCP***

Common request form for RMS

Links to NCAs webpages - Recommendations for requests to act as RMS

---

### o ***MRP***

Flow chart of the Mutual Recognition Procedure

Guidance on submission dates for Applicants of the Mutual Recognition Procedure

Guidance document - Assessment Report MRP Overview

---

### ❖ **eSubmissions** (<http://www.hma.eu/277.html>)

CMDh BPG on the use of eCTD in MRP/DCP

Requirements on eSubmissions for NA within MRP, DCP or National procedures

Requirements on eSubmissions for Renewals and Variations within MRP, DCP or National procedures

Questions & Answers - The use of eCTD on MRP/DCP

---

### ❖ **Generics in MRP and DCP** (<http://www.hma.eu/211.html>)

CMDh Position paper on processing of generic applications when the generic has more indications or fewer indications than the reference product in the CMS

## Documents

Information to be submitted by the Member State of the European Reference Medicinal Product

CMDh Recommendation for Applications submitted according to Article 10 when the strength and/or the pharmaceutical form of the reference medicinal product differs between RMS/CMS(s)

CMDh Recommendations on Implementation of Article 30 Decisions for Generic /Hybrid/Biosimilar Medicinal Products approved through MRP/DCP

---

❖ **Applicants' Responses** (<http://www.hma.eu/98.html>)

Applicant's Response Document in Mutual Recognition -Recommended (CTD-Format )

---

❖ **Renewal Procedure** (<http://www.hma.eu/95.html>)

CMDh BPG on the processing of renewals in the MRP/DCP

Common grounds seen for delaying Day 0 Renewals

---

❖ **Variation Procedure** (<http://www.hma.eu/96.html>)

Best Practice Guides for the Submission and Processing of Variations in the Mutual Recognition Procedure

European Medicines Agency/CMDh explanatory notes on Variation Application Form (Human medicinal products only)

Examples for acceptable and not acceptable groupings for MRP/DCP products

Position paper on common grounds seen for invalidation/delaying Day 0 for Variations

Cover letter for Variation applications in Mutual Recognition Procedure

Questions & Answers - List for the Submission of Variations according to Commission Regulation (EC) 1234/2008

## Documents

Implementation of Variation Regulation 1234/2008 in each Member State for Medicinal Products authorised by purely national procedures

Data requested for Variations and/or Renewal Applications in the MRP/DCP

---

o **Art.5 on Unforeseen Variations** (<http://www.hma.eu/293.html>)

Timetables 2011 for request to CMDh for a recommendation on the classification of an unforeseen variation - Article 5

Timetables for request to CMDh for a recommendation on the classification of an unforeseen variation-Article 5

CMDh Recommendation for classification of unforeseen variations according to Article 5 of Commission Regulation (EC) No 1234/2008

---

❖ **Urgent Safety Restriction** (<http://www.hma.eu/102.html>)

Urgent Safety Restriction Members States' Standard Operating Procedure

---

❖ **Art. 61(3) Procedure** (<http://www.hma.eu/101.html>)

CMDh Standard Operating Procedure for Article 61(3) changes to patient information and the notification for product information amendment under Article 61(3) (not accompanying a variation change)

Flow-chart for the Article 61(3) procedure

Notification Form

---

❖ **Consultation with target patient groups** (<http://www.hma.eu/218.html>)

Consultation with target patient groups meeting the requirements of Article 59(3) without the need for a full test.- Recommendations for bridging

Position paper on user testing of package leaflets

---

❖ **Post referral phase** (<http://www.hma.eu/100.html>)

## Documents

---

Recommendation for Mutual Recognition Procedure after finalisation of a referral procedure with a positive decision by the EC

---

❖ **Pandemic Plan** (<http://www.hma.eu/276.html>)

CMDh Pandemic Plan - Maintaining CMDh Core and Critical Business during a Pandemic Influenza Outbreak + Annexes

---

## CMDh Referrals (<http://www.hma.eu/26.html>)

Overview of timetables 2011

CMDh Standard Operating Procedure - Disagreement in procedures referred to CMDh (incl. Annex Guidance on OE to CMDh)

Guidance on oral explanations to CMDh - Annex to CMDh SOP on Disagreement in Procedures, Referral to CMDh

Questions & Answers on the SOP Disagreement in Procedures, Referral to CMDh

***Information on applications referred to the CMDh in accordance with Article 29(1) of Directive 2001/83/EC***

Tracking table

---

## Product Information

---

❖ **PhVWP Recommendations** (<http://www.hma.eu/222.html>)

*Insulin products and risk of cardiac failure with concomitant use of pioglitazone*

*Fluoroquinolones and risk of QT-interval prolongation*

*Risk of psychiatric adverse drug reactions to inhaled and intranasal corticosteroids and risk of non-psychiatric systemic adverse drugs reactions to intranasal corticosteroids*

*Long-Acting Beta Agonists (LABAs) - Increased risk of exacerbation of asthma symptoms*

## Documents

*Tamoxifen and the risk of variability in clinical response due to CYP2D6 genetic variants or when given with CYP2D6 inhibitors*

*Alendronate and the risk of oesophageal cancer*

*Camphor containing ointments and risk of unintended oral ingestion*

*Rosuvastatin and the risk of diabetes mellitus*

*Isotretinoin and the risk of erythema multiforme*

*SSRIs, venlafaxine and mirtazapine*

*And the risk of Persistent Pulmonary Hypertension in Neonates (PPHN)*

*SSRIs and TCAs and the risk of bone fractures*

*Fluoxetine and the risk of Congenital Malformations*

*Propylthiouracil and the risk of serious liver injury*

*Valproic Acid and the risk of interaction with carbapenems*

*Cyproterone acetate and the risk of meningiomas*

*Association of HMG-CoA Reductase Inhibitors with safety concerns: sleep disturbances; memory loss; micturition disorders; sexual disturbance; depression; interstitial pneumopathy*

*Phenytoin-related SJS in association with HLA-B\*1502 allele in individuals of Thai or Han Chinese origin*

*Apomorphine containing products and risk of QT interval prolongation*

*Short-acting beta agonists and risk of myocardial ischemia*

*Conventional (Typical) Antipsychotics and increased mortality in elderly people with dementia*

## Documents

*Antipsychotics and risk of venous thromboembolism (VTE)*

*Vigabatrin and MRI abnormalities and movement disorders*

*Ceftriaxone and the risk of precipitation when given with calcium-containing solutions*

*Alendronic acid and the risk of stress fractures of the proximal femoral shaft*

*Additional hypotensive effects following co-administration of non-selective alpha-blockers and phosphodiesterase-5-inhibitors*

*Hydrochlorothiazide and use during pregnancy*

*Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Antagonists (AIIIRAs): Use during pregnancy & lactation*

*Bisphosphonates and Atrial fibrillation*

*Ibuprofen & Aspirin*

*Antiepileptics and suicidal behaviour*

*Carbamazepine related Stevens Johnson Syndrome and association with HLA-B\*1502*

*Antidepressants and suicidal thoughts and behaviour*

*Beta-blocking agents for ophthalmic use and systemic adverse drug reactions after ophthalmic administration*

*Hydrochlorothiazide (HCTZ) and use in lactation + consolidated wording for the SmPC and PL of ACE-inhibitors alone or in combination with HCTZ in pregnancy and lactation*

*Paracetamol use at therapeutic doses in severe hepatic impairment or severe haemolytic anaemia*

*Citalopram and the risk of QT prolongation*

## Documents

*Antipsychotics (conventional and atypical) and use during the third trimester of pregnancy and risk of abnormal muscle movements and/or withdrawal symptoms in newborns*

*Plantago ovata seeds and allergic reactions after prolonged occupational exposure*

*Key elements for SmPC and PL regarding Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) for 14 "high risk" substances (for systemic use)*

*Domperidone and risk of QTc prolongation, serious ventricular arrhythmias and sudden cardiac death*

*Effect of Strattera (atomoxetine) on blood pressure and heart rate from review of MAH clinical trial database*

---

### ❖ **CMDh Recommendations** (<http://www.hma.eu/245.html>)

*Azithromycin containing products in patients with severe hepatic impairment*

*Oxycodone containing medicinal products*

---

### ❖ **Harmonisation of SPCs - Article 30** (<http://www.hma.eu/261.html>)

***Information on applications referred in accordance with Article 30 of Directive 2001/83/EC***

Tracking Table

---

### ❖ **Core SPC/PL** (<http://www.hma.eu/104.html>)

***Trivalent Influenza Vaccines***

Core Summary Product Characteristics

Core Package Leaflet

***Core SPCs***

## Documents

Fludeoxyglucose (18FDG) - Revised Core SPC and PL

Hormone Replacement Therapy - Core SPC

Hormone Replacement Therapy - MRFG-PhVWP agreed updated core SPC

Hormone Replacement Therapy - SPC wording for medicinal products used in HRT with regard to increased risk of venous thromboembolism as agreed by the PhVWP

Hormone Replacement Therapy - SPC wording for medicinal products used in HRT with regard to increased risk of breast cancer as agreed by the PhVWP

Hormone Replacement Therapy – Core Package Leaflet

---

### **Advice from CMDh** (<http://www.hma.eu/226.html>)

*Bio-analytical studies conducted at Cetero Research Houston, Texas (former BA Research)*

*Monitoring of medicines originating from Japan*

***Abbreviated core Risk Management Plan for bisphosphonates***

*Guidance on the submission/updating of Risk Management Plans to reflect 'atypical femoral fractures'*

*Abbreviated core bisphosphonate RMP for atypical femoral fracture*

***EU Worksharing Procedure***

Public Assessment Report - Change in qualitative and quantitative composition of rubber stoppers of West Pharmaceutical Services

## Documents

Monitoring of medicines originating from Japan (August 2011)

## Templates

- ❖ **QRD Templates** (<http://www.hma.eu/126.html>)

CMDh QRD annotated template for MRP/DCP

- ❖ **Assessment Reports** (<http://www.hma.eu/108.html>)

- **DCP (AR/Comments)** (<http://www.hma.eu/127.html>)

Non Clinical / Clinical AR for Generics - MRP & DCP

D70 Preliminary AR

D100 CMS Comments

D105 Clock stop

D120 Finalisation (opt.)

D120 Draft AR

D145 CMS comments

D150 Finalisation (opt.)

D180 RMS report to CMDh

D205 CMS Comments

## Documents

D210 Finalisation

---

Assessment Report Feedback Form

Assessment Report on Active Substance Master File (ASMF)

---

○ **MRP** (<http://www.hma.eu/110.html>)

Template Assessment Report MRP Overview

Template CMS comments in MRP

Template Non Clinical / Clinical AR for Generics - MRP & DCP

---

○ **Renewals** (<http://www.hma.eu/238.html>)

Template - Preliminary Renewal Assessment Report

Template - RMS End of Renewal Procedure

---

○ **Variations** (<http://www.hma.eu/112.html>)

Type II variation

Preliminary Variation Assessment Report

Type II variation

Final Variation Assessment Report

Template for the outcome of variation worksharing procedures

---

○ **Art. 61.3 Procedure** (<http://www.hma.eu/128.html>)

Notification form

---

## Documents

---

- **Public AR** (<http://www.hma.eu/114.html>)

PAR Scientific discussion

PAR update

---

- **Paediatric Data** (<http://www.hma.eu/193.html>)

### ***Assessment on Paediatric Data***

Template for the Paediatric assessment report

### ***Paediatric Regulation: Article 45***

Rapporteur's Preliminary/Final AR for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No 1901/2006, as amended

### ***Paediatric Regulation: Article 46***

Rapporteur's Preliminary/Final AR for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No 1901/2006, as amended

### ***Comments from the competent authority on the Paediatric work sharing PAR: Article 45 & 46***

Template on the Paediatric work sharing preliminary AR

---

- ❖ **Applications for MA** (<http://www.hma.eu/219.html>)

### ***Applications for Marketing Authorisation***

Template: Cover letter for new applications submitted through MRP/DCP

### ***Request for RMS in a Decentralised Procedure, medicinal products for human use***

## Documents

---

Common request form

### ***Validation***

Template on Validation for Application on Marketing Authorisation

---

### ❖ **Art.29 Referrals to CMDh** (<http://www.hma.eu/262.html>)

Referral to CMDh (RMS)

D90/210 referral request (CMS)

---

### ❖ **Variations** (<http://www.hma.eu/265.html>)

#### ***Request to CMDh for a recommendation on the classification of an unforeseen variation under Article 5***

Template Request form for recommendation - Article 5

Template Recommendation form - Article 5

Template of letter of intent for the submission of a worksharing procedure

---

## **CMD Subgroups / working groups** (<http://www.hma.eu/86.html>)

### ❖ **Working Party on the Future of the CMDh** (<http://www.hma.eu/279.html>)

#### ***Working Party on the Future of the CMDh***

Mandate for the Working Party on the Future of the CMDh

---

## Documents

❖ **Subgroup on Paediatric Regulation** (<http://www.hma.eu/272.html>)

***Subgroup on Paediatric Regulation***

Mandate for the CMDh Subgroup on Paediatric Regulation

***Work plan 2011***

Workplan 2011 on Paediatric Regulation

***Statistics on Paediatric Regulation***

Statistics on Member States acting as rapporteurs in Paediatric worksharing procedures

---

❖ **Subgroup on Variations** (<http://www.hma.eu/243.html>)

Mandate for the Subgroup on Variations

---

❖ **Subgroup on Harmonisation of SPCs** (<http://www.hma.eu/242.html>)

***CMDh Subgroup on Harmonisation of SPCs***

Mandate for the CMDh Subgroup on Harmonisation of SPCs

***Lists of Medicinal Products for Harmonisation of SPCs***

Final list of products for SPC Harmonisation - 2010

Criteria for selection of products for SPC Harmonisation

---

❖ **Joint CMDh/PhVWP WG** (<http://www.hma.eu/275.html>)

## Documents

Mandate Joint Subgroup CMDh-PhVWP

CMDh and PhVWP Best Practice Guide on communication and implementation of safety information

---

❖ **CTS Working group** (<http://www.hma.eu/294.html>)

Mandate CTS Working Group

---

❖ **Working Group on Active Substance Master File Procedures** (<http://www.hma.eu/306.html>)

Mandate of the Working Group on Active Substance Master File Procedures

---

❖ **GCP/CMDh Subgroup** (<http://www.hma.eu/307.html>)

Mandate of the Joint CMDh/GCP Inspectors Subgroup

---

## **Paediatric Regulation** (<http://www.hma.eu/213.html> )

❖ **Guidance Documents** (<http://www.hma.eu/216.html> )

***Paediatric Worksharing***

Recommendations on submission and assessment in paediatric worksharing

***Paediatric Regulation: Article 45***

Best Practice Guide Article 45 - EU Worksharing procedure

***Paediatric Regulation: Article 46***

Best Practice Guide Article 46 - EU Worksharing procedure

## Documents

Cover letter- Submission of information about paediatric studies completed after 26 January 2007 in accordance with Article 46 of Regulation No 1901/2006

Line listing

---

### ***Public Assessment Reports***

Best Practice Guide for the preparation of the Public Assessment Report in the EU Worksharing project for the assessment of paediatric data

### ***Paediatric Regulation: Article 29***

Recommendations for implementing Commission Decisions following an Art. 29 Application under the Paediatric Regulation

### ***Compliance statement for the agreed completed PIP***

Recommendation for implementation of compliance statement for the agreed completed PIP

Template on compliance statement for the agreed completed PIP

### ***PUMA***

Recommendations on Paediatric Use Marketing Authorisations

### ***Q&A Paediatric Regulation***

Questions & Answers on the Paediatric Regulation

---

### ❖ **Article 45 and previous Worksharing** (<http://www.hma.eu/99.html>)

#### ***Worksharing on Article 45***

List of the active substances included in the work-sharing procedure

## Documents

List of active substances for which data has been submitted in accordance with Article 45 of the Paediatric Regulation

---

### ***Worksharing project on paediatric data***

List of active substances and agreed SPC wordings - EU work sharing procedure in the assessment of paediatric data

---

#### ❖ **Assessment Reports** (<http://www.hma.eu/187.html>)

---

- **Article 45 work-sharing** (<http://www.hma.eu/269.html>)
  - **Article 46 work-sharing** (<http://www.hma.eu/291.html>)
  - **Previous worksharing project** (<http://www.hma.eu/270.html>)
- 

## **Questions and Answers** (<http://www.hma.eu/20.html>)

#### ❖ **Applications for MA** (<http://www.hma.eu/227.html>)

***Possibility to follow the DCP for a 'duplicate application' of a medicinal product in the MRP***

***Possibility to follow the DCP for an extension application of a medicinal product in the MRP***

***Article 17(2) of Directive 2001/83/EC, as amended***

***Article 18 of Directive 2001/83/EC, as amended***

***Information on fees payable to Member States in the MRP/DCP***

***Communication***

***General information on national requirements***

## Documents

*Bibliographical applications and mutual recognition/national procedure*

---

*Combination Packages*

*Manufacturing sites restricted to particular Member States in the MRP and DCP*

*Change in the name of a medicinal product prior to granting a Marketing Authorisation*

---

❖ **CMDh Referrals** (<http://www.hma.eu/119.html>)

*Scope of the procedure*

*Before start of the procedure*

*Initiating the procedure*

*Timetable*

*List of questions*

*Issues for discussion*

*Outcome of procedure*

*Withdrawals*

*Involvement of non-concerned Member States*

*After the 60 days procedure*

---

❖ **Variations** (<http://www.hma.eu/120.html>)

## Documents

*Simplified handling of Variations*

*Generals*

*Transfer of Marketing Authorisation*

*Numbering of follow-up submissions and commitments*

*Submission of Variations before a Marketing Authorisation has been granted*

---

❖ **Post referral phase** (<http://www.hma.eu/234.html>)

*Harmonisation of SPCs*

*Article 29(4) Referrals*

*Suspension of Marketing Authorisation following a referral according to Art. 29(4) of Directive 2001/83/EC*

---

❖ **PSUR &Renewals** (<http://www.hma.eu/232.html>)

---

○ *PSURs* (<http://www.hma.eu/233.html>)

*PSURs cycle*

*PSURs submission*

---

○ *Renewals* (<http://www.hma.eu/217.html>)

*Application for the renewal of a Marketing Authorisation*

---

❖ **Product Information / Information on medicinal products** (<http://www.hma.eu/228.html>)

## Documents

*Languages to be used for applications for marketing authorisation in the Decentralised or Mutual Recognition Procedure*

*Languages to be used for applications for variations and renewals to marketing authorisations granted via the Decentralised or Mutual Recognition Procedure*

*Consultation with target patient groups for the Package Leaflet*

*Braille*

*Public Assessment Reports*

*Information on marketing of medicinal products*

*List of Mutual Recognition products*

*Question & Answer on the implementation of QRD templates for package leaflets*

---

❖ **Generics & Usage Patents** (<http://www.hma.eu/229.html>)

---

○ **Generic Applications** (<http://www.hma.eu/210.htm> )

*Questions & Answers on submission of a description of Pharmacovigilance system and EU Risk Management Plans for Generic and Hybrid Applications*

*Possibility to refer to clinical studies performed by a Company different from the Company holding the initial Marketing Authorisation*

*Legal basis for Generic Applications where the Reference Medicinal Product in the CMS(s) has fewer indication(s) than in the RMS*

*Possibility to use a Medicinal Product authorised in a Member State prior to its accession to the EU as Reference Medicinal Product for the purpose of the data exclusivity period*

*Compliance with Commission Decisions after referral procedures*

*Reference products for bioequivalence studies*

---

## Documents

### *Naming of Generics*

### *Legal basis for products for local use*

---

- *Usage Patents* (<http://www.hma.eu/117.html>)
- 

- ❖ **Biologicals** (<http://www.hma.eu/215.html>)
- 

- ❖ **Homeopathics** (<http://www.hma.eu/214.html>)
- 

### *Number of application forms for registration of homeopathic medicinal products*

---

- ❖ **Advice from CMDh** (<http://www.hma.eu/192.html>)
- 

- ❖ **EU-Enlargement** (<http://www.hma.eu/118.html>)
- 

### *Questions & Answers on MRP & DCP after the EU Enlargement on 1 May 2004 & 1 January 2007*

---

**Contact Form** (<http://www.hma.eu/68.html>)

---

**Contact Points** (<http://www.hma.eu/69.html>)

---

### *Advice on MRP and DCP*

### *Submission of electronic response documents in MRP and DCP*

Contact e-mail addresses for submission of electronic response documents during MRP and DCP

### *Submission of Translations in MRP and DCP*

Contact addresses for submission of translations in MRP and DCP

---

## Documents

---

### ***Submission of Responses to List of Questions for Applications referred to the CMDh***

Contact e-mail addresses for submission of electronic version of the Responses to the List of Questions for Applications referred to the CMDh

### ***Contact addresses for the submission of Paediatric information in Member States***

Submission of Paediatric information in Member States (Articles 45 and 46 of the Regulation of the European Parliament and of the Council (EC) No 1901/2006)

### ***Submission of Variation Grouping Number***

Contact e-mail addresses for submission on Variation Grouping Numbers

Search for Contact points

---

**What's New History** (<http://www.hma.eu/186.html>)

---